Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
The first advance in the history of studies on prostate cancer (PCa) and androgens was the development of treatment with castration and administration of estrogen by Charles B. Huggins, who won the Nobel Prize in Physiology and Medicine. Since then, and for 70 years, androgen deprivation therapy has...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165281/ |
| id |
pubmed-4165281 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-41652812014-10-02 Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? Kosaka, Takeo Miyajima, Akira Oya, Mototsugu Oncology The first advance in the history of studies on prostate cancer (PCa) and androgens was the development of treatment with castration and administration of estrogen by Charles B. Huggins, who won the Nobel Prize in Physiology and Medicine. Since then, and for 70 years, androgen deprivation therapy has been the standard therapy for advanced PCa and the center of studies on PCa. However, recent advances have shed light on the relationship between androgens and the development or the progression of PCa. The use of 5AR inhibitors to prevent progression of PCa continues to be widely discussed. Discussion has been fueled by the findings of two large randomized, placebo-controlled trials: the Prostate Cancer Prevention Trial with finasteride and the Reduction by Dutasteride of Prostate Cancer Events trial. Does the development of PCa or progression to castration-resistant PCa depend on dihydrotestosterone (DHT)? Here, we summarize and discuss recent topics of local androgen production of DHT in PCa. Frontiers Media S.A. 2014-09-16 /pmc/articles/PMC4165281/ /pubmed/25279351 http://dx.doi.org/10.3389/fonc.2014.00247 Text en Copyright © 2014 Kosaka, Miyajima and Oya. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Kosaka, Takeo Miyajima, Akira Oya, Mototsugu |
| spellingShingle |
Kosaka, Takeo Miyajima, Akira Oya, Mototsugu Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? |
| author_facet |
Kosaka, Takeo Miyajima, Akira Oya, Mototsugu |
| author_sort |
Kosaka, Takeo |
| title |
Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? |
| title_short |
Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? |
| title_full |
Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? |
| title_fullStr |
Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? |
| title_full_unstemmed |
Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? |
| title_sort |
is dht production by 5α-reductase friend or foe in prostate cancer? |
| description |
The first advance in the history of studies on prostate cancer (PCa) and androgens was the development of treatment with castration and administration of estrogen by Charles B. Huggins, who won the Nobel Prize in Physiology and Medicine. Since then, and for 70 years, androgen deprivation therapy has been the standard therapy for advanced PCa and the center of studies on PCa. However, recent advances have shed light on the relationship between androgens and the development or the progression of PCa. The use of 5AR inhibitors to prevent progression of PCa continues to be widely discussed. Discussion has been fueled by the findings of two large randomized, placebo-controlled trials: the Prostate Cancer Prevention Trial with finasteride and the Reduction by Dutasteride of Prostate Cancer Events trial. Does the development of PCa or progression to castration-resistant PCa depend on dihydrotestosterone (DHT)? Here, we summarize and discuss recent topics of local androgen production of DHT in PCa. |
| publisher |
Frontiers Media S.A. |
| publishDate |
2014 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165281/ |
| _version_ |
1613134262140141568 |